Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($9.21), $6.11 worse than the analyst estimate of ($3.10).Second Quarter 2019 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Earnings Management Comments

Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business HighlightsAugust 26, 2019 7:01 AM